Survival Rate of Non-epithelial Ovarian Tumors in Iran

IF 0.4 Q4 ONCOLOGY

Middle East Journal of Cancer Pub Date : 2020-10-10 DOI:10.30476/MEJC.2020.82925.1124

S. Bolandi, M. Nakhaee, L. Shirinzadeh, A. Jafarian, B. Davachi, T. Zavari, Fatemeh Shirzadeh, Z. Yousefi

{"title":"Survival Rate of Non-epithelial Ovarian Tumors in Iran","authors":"S. Bolandi, M. Nakhaee, L. Shirinzadeh, A. Jafarian, B. Davachi, T. Zavari, Fatemeh Shirzadeh, Z. Yousefi","doi":"10.30476/MEJC.2020.82925.1124","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to estimate the overall survival and relapse free survival (RFS) of the non-epithelial ovarian tumors (NEOTs) of ovarian germ cell tumors (OGCT) and ovarian sex cord tumors (OSCT) in Iranian women; we also evaluated the relative prognostic factors. \nMethod: In this retrospective study, we screened the documents of all the women diagnosed with OGCTs and OSCTs from 2012 to 2019. We further assessed the overall survival (OS), relapse free survival (RFS), and different prognostic factors. \nResults: A statistically significant association existed between RFS and stage of the disease at diagnosis in OSCTs group by univariate analysis and multivariate analysis (HR: 0.25 (95% CI (0.08-0.78), p-value: 0.01) and multivariate analysis (HR: 0.27 (95% CI (0.08-0.97), p-value: 0.04), respectively. The kaplan-meier analysis and the Log Rrank (Mantel-Cox) showed a statistically significant relationship between the stage at diagnosis and RFS in OGCT group (P-value=0.042). RFS was 96% for OGCT patients, and 92.7% for OSCT patients. During the follow-up, only one patient passed away in the dysgerminoma group; the OS rate was 98% for OGCT patients, and 100% for OSCT patients. \nConclusion: The overall survival and RFS obtained in this study confirmed that the ovarian germ cell and sex cord malignancies were among the highly treatable solid tumors. Stage can be proposed as the main prognostic factor; also, larger series of studies are needed for detecting the prognostic significance of serum markers.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2020-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/MEJC.2020.82925.1124","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study was to estimate the overall survival and relapse free survival (RFS) of the non-epithelial ovarian tumors (NEOTs) of ovarian germ cell tumors (OGCT) and ovarian sex cord tumors (OSCT) in Iranian women; we also evaluated the relative prognostic factors. Method: In this retrospective study, we screened the documents of all the women diagnosed with OGCTs and OSCTs from 2012 to 2019. We further assessed the overall survival (OS), relapse free survival (RFS), and different prognostic factors. Results: A statistically significant association existed between RFS and stage of the disease at diagnosis in OSCTs group by univariate analysis and multivariate analysis (HR: 0.25 (95% CI (0.08-0.78), p-value: 0.01) and multivariate analysis (HR: 0.27 (95% CI (0.08-0.97), p-value: 0.04), respectively. The kaplan-meier analysis and the Log Rrank (Mantel-Cox) showed a statistically significant relationship between the stage at diagnosis and RFS in OGCT group (P-value=0.042). RFS was 96% for OGCT patients, and 92.7% for OSCT patients. During the follow-up, only one patient passed away in the dysgerminoma group; the OS rate was 98% for OGCT patients, and 100% for OSCT patients. Conclusion: The overall survival and RFS obtained in this study confirmed that the ovarian germ cell and sex cord malignancies were among the highly treatable solid tumors. Stage can be proposed as the main prognostic factor; also, larger series of studies are needed for detecting the prognostic significance of serum markers.

查看原文本刊更多论文

伊朗非上皮性卵巢肿瘤的生存率

背景：本研究的目的是评估伊朗妇女非上皮性卵巢肿瘤（NEOT）、卵巢生殖细胞肿瘤（OGCT）和卵巢性索肿瘤（OSCT）的总生存率和无复发生存率（RFS）；我们还评估了相关的预后因素。方法：在这项回顾性研究中，我们筛选了2012年至2019年所有被诊断为OGCT和OSCT的女性的文件。我们进一步评估了总生存率（OS）、无复发生存率（RFS）和不同的预后因素。结果：单因素分析、多因素分析（HR:0.25（95%CI（0.08-0.78），p值：0.01）和多因素分析，OSCTs组的RFS与诊断时的疾病分期之间存在统计学上显著的相关性（HR:0.27（95%CI（0.08-0.97），p值：0.04）。kaplan-meier分析和Log-Rrank（Mantel-Cox）显示，OGCT组的诊断分期与RFS之间存在统计学显著关系（P值=0.042）。OGCT患者的RFS为96%，OSCT患者为92.7%。在随访期间，无性细胞瘤组只有一名患者去世；OGCT患者和OSCT患者的OS率分别为98%和100%。结论：本研究获得的总生存率和RFS证实，卵巢生殖细胞和性索恶性肿瘤是高度可治疗的实体瘤。阶段可以被认为是主要的预后因素；此外，还需要更大规模的研究来检测血清标志物的预后意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Middle East Journal of Cancer ONCOLOGY-

CiteScore

0.80

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： Middle East Journal of Cancer (MEJC) is an international peer-reviewed journal which aims to publish high-quality basic science and clinical research in the field of cancer. This journal will also reflect the current status of research as well as diagnostic and treatment practices in the field of cancer in the Middle East, where cancer is becoming a growing health problem. Lastly, MEJC would like to become a model for regional journals with an international outlook. Accordingly, manuscripts from authors anywhere in the world will be considered for publication. MEJC will be published on a quarterly basis.